journal article·2013-06-26

pH-Responsive Biodegradable Assemblies Containing Tunable Phenyl-Substituted Vinyl Ethers for Use as Efficient Gene Delivery Vehicles

Hee-Kwon Kim, David H. Thompson, Ho Seong Jang, Yong Jin Chung, Jeroen Van den Bossche

Publisher page

Abstract

Novel pH-responsive assemblies (PEG-lipid:DOPE liposomes) containing tunable and bifunctional phenyl-substituted vinyl ether (PIVE) cross-linkers were prepared. The assemblies consisted of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), acid-cleavable poly(ethylene glycol) (PEG)-conjugated lipids, pDNA, and protamine sulfate (PS). The PIVE linkage was designed to hydrolyze under acidic conditions, and the hydrolysis studies of PEG-lipid compounds containing PIVE at pH 4.2, 5.4, and 7.4 indicated that the hydrolysis rates of PIVE linker were influenced by the substitution of electron withdrawing or electron donating groups on the phenyl ring. Acid-catalyzed hydrolysis of PIVE leads to destabilization of the acid labile PEG-PIVE-lipid:DOPE liposomes via dePEGylation, thereby triggering content release. Content release assays showed that dePEGylation was highly pH-dependent and correlated with the PIVE proton affinity of the phenyl group. These results indicated that the dePEGylative triggering based on a new pH-sensitive PIVE linkage can be controlled. In vitro transfection studies on the pH-responsive assemblies containing mPEG-(MeO-PIVE)-conjugated 1,3-dioctadecyl-rac-glycerol lipids (mPEG-(MeO-PIVE])-DOG) showed higher transfection efficiency compared to that of polyethylenimine (PEI), a positive control, on HEK 293 and COS-7 cells. In addition, lower cytotoxicity of PEG-PIVE-lipid:DOPE liposomes/PS/DNA was observed in comparison to PEI. These results suggest that PEG-PIVE-lipid:DOPE liposomes can be considered as nonviral vehicles for drug and gene delivery applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States

Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States

Nano Materials Center, Korea Institute of Science and Technology, Seoul, 136-791, Republic of Korea

Chemical and Materials Engineering Department, California State Polytechnic University, Pomona, 3801 West Temple Avenue, Pomona, California 91768, United States

Nanomedicine Laboratory, Centre for Drug Delivery Research, The School of Pharmacy, University of London, 29−39 Brunswick Square, London WC1N 1AX, United Kingdom

References (65)

Show source-provided references
1. Mancuso K. · Nature · 2009 · 461 · 78410.1038/nature08401 ↗
2. Semple S. C. · Nat. Biotechnol. · 2010 · 20 · 17210.1038/nbt.1602 ↗
3. Waehler R. · Nat. Rev. Genet. · 2007 · 8 · 57310.1038/nrg2141 ↗
4. Mintzer M. A. · Chem. Soc. Rev. · 2011 · 40 · 17310.1039/B901839P ↗
5. Xu L. · Pharm. Sci. · 2011 · 100 · 3810.1002/jps.22243 ↗
6. Wiethoff C. M. · J. Pharm. Sci. · 2003 · 92 · 20310.1002/jps.10286 ↗
7. Pack D. W. · Nat. Rev. Drug Discovery · 2005 · 4 · 58110.1038/nrd1775 ↗
8. Watson P. · Adv. Drug Delivery Rev. · 2005 · 57 · 4310.1016/j.addr.2004.05.003 ↗
9. Gerweck L. E. · Semin. Radiat. Oncol. · 1998 · 8 · 17610.1016/S1053-4296(98)80043-X ↗
10. Mellman I. · Annu. Rev. Biochem. · 1986 · 55 · 66310.1146/annurev.bi.55.070186.003311 ↗
11. Daleke D. L. · Biochim. Biophys. Acta · 1990 · 1024 · 35210.1016/0005-2736(90)90365-U ↗
12. Straubinger R. M. · Biochemistry · 1990 · 29 · 492910.1021/bi00472a025 ↗
13. Lee R. J. · Biochim. Biophys. Acta · 1996 · 1312 · 23710.1016/0167-4889(96)00041-9 ↗
14. Sun H. H. · J. Biomed. Nanotechnol. · 2009 · 5 · 67610.1166/jbn.2009.1084 ↗
15. Rofstad E. K. · Cancer Res. · 2006 · 66 · 669910.1158/0008-5472.CAN-06-0983 ↗
16. Brune K. · Biochem. Pharmacol. · 1978 · 27 · 52510.1016/0006-2952(78)90388-X ↗
17. Masson C. · J. Control. Release · 2004 · 99 · 42310.1016/j.jconrel.2004.07.016 ↗
18. Huang Z. H. · J. Am. Chem. Soc. · 2006 · 128 · 6010.1021/ja057024w ↗
19. Chen H. G. · J. Med. Chem. · 2007 · 50 · 426910.1021/jm060128c ↗
20. Remenyi J. · Biochem. Biophys. Res. Comm. · 2003 · 303 · 55610.1016/S0006-291X(03)00394-2 ↗
21. Alshamkhani A. · Int. J. Pharm. · 1995 · 122 · 10710.1016/0378-5173(95)00055-N ↗
22. Kale A. A. · Bioconjugate Chem. · 2007 · 18 · 36310.1021/bc060228x ↗
23. Sawant R. M. · Bioconjugate Chem. · 2006 · 17 · 94310.1021/bc060080h ↗
24. Knorr V. · Bioconjugate Chem. · 2008 · 19 · 162510.1021/bc8001858 ↗
25. Gillies E. R. · Bioconjugate Chem. · 2004 · 15 · 125410.1021/bc049853x ↗
26. Parrott M. C. · J. Am. Chem. Soc. · 2010 · 132 · 1792810.1021/ja108568g ↗
27. Boomer J. A. · Langmuir · 2003 · 19 · 640810.1021/la030104y ↗
28. Boomer J. A. · Bioconjugate Chem. · 2009 · 20 · 4710.1021/bc800239b ↗
29. Felber A. E. · Adv. Drug Delivery Rev. · 2012 · 64 · 97910.1016/j.addr.2011.09.006 ↗
30. Hope M. J. · Biochim. Biophys. Acta · 1985 · 812 · 5510.1016/0005-2736(85)90521-8 ↗
31. Mayer L. D. · Biochim. Biophys. Acta · 1986 · 857 · 12310.1016/0005-2736(86)90105-7 ↗
32. Lasic D. D. · FEBS Lett. · 1992 · 312 · 25510.1016/0014-5793(92)80947-F ↗
33. Haran G. · Biochim. Biophys. Acta · 1993 · 1151 · 20110.1016/0005-2736(93)90105-9 ↗
34. Jain R. K. · Adv. Drug Delivery Rev. · 2001 · 46 · 14910.1016/S0169-409X(00)00131-9 ↗
35. Maeda H. · Bioconjugate Chem. · 2010 · 21 · 79710.1021/bc100070g ↗
36. Leserman L. D. · Nature · 1980 · 288 · 60210.1038/288602a0 ↗
37. Rui Y. · J. Am. Chem. Soc. · 1998 · 120 · 1121310.1021/ja9742949 ↗
38. Hussain S. · Mol. Cancer Ther. · 2007 · 6 · 301910.1158/1535-7163.MCT-07-0615 ↗
39. Chen H. · Mol. Cancer Ther. · 2009 · 8 · 195510.1158/1535-7163.MCT-09-0045 ↗
40. Qualls M. M. · Int. J. Cancer · 2001 · 93 · 38410.1002/ijc.1339 ↗
41. Harris J. M. · Nat. Rev. Drug Discovery · 2003 · 2 · 21410.1038/nrd1033 ↗
42. Jin Y. · Acta Biomaterialia · 2012 · 8 · 337210.1016/j.actbio.2012.05.022 ↗
43. Holland J. W. · Biochemistry · 1996 · 35 · 261010.1021/bi951999j ↗
44. Li W. M. · Biochim. Biophys. Acta · 2001 · 1513 · 19310.1016/S0005-2736(01)00351-0 ↗
45. Auguste D. T. · Biochim. Biophys. Acta · 2003 · 1616 · 18410.1016/j.bbamem.2003.08.007 ↗
46. Kirpotin D. · FEBS Lett. · 1996 · 388 · 11510.1016/0014-5793(96)00521-2 ↗
47. Sega E. I. · Cancer Metast. Rev. · 2008 · 27 · 65510.1007/s10555-008-9155-6 ↗
48. Shin J. · Mol. Pharm. · 2012 · 9 · 326610.1021/mp300326z ↗
49. Sanchez M. · Chem. Phys. Lipids · 2011 · 164 · 1610.1016/j.chemphyslip.2010.09.008 ↗
50. Bergstrand N. · Biophys. Chem. · 2003 · 104 · 36110.1016/S0301-4622(03)00011-5 ↗
51. Shin J. · J. Control. Release · 2003 · 91 · 18710.1016/S0168-3659(03)00232-3 ↗
52. Kim H.-K. · Bioconjugate Chem. · 2012 · 23 · 207110.1021/bc300266y ↗
53. Sorgi F. L. · Gene Ther. · 1997 · 4 · 96110.1038/sj.gt.3300484 ↗
54. Gao Y. · J. Control. Release · 2007 · 118 · 38110.1016/j.jconrel.2007.01.006 ↗
55. Nie Y. · Biomaterials · 2011 · 32 · 85810.1016/j.biomaterials.2010.09.032 ↗
56. Balhorn R. · Mol. Reprod. Dev. · 2000 · 56 · 23010.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.0.CO;2-V ↗
57. Biegeleisen K. · J. Theor. Biol. · 2006 · 241 · 53310.1016/j.jtbi.2005.12.015 ↗
58. Yuan H. · Int. J. Pharm. · 2010 · 392 · 22410.1016/j.ijpharm.2010.03.025 ↗
59. Evjen T. J. · Int. J. Pharm. · 2011 · 406 · 11410.1016/j.ijpharm.2010.12.026 ↗
60. Johnsson M. · Biophys. J. · 2001 · 80 · 31310.1016/S0006-3495(01)76016-X ↗
61. Klein E. · Bioconjugate Chem. · 2010 · 21 · 36010.1021/bc900469z ↗
62. Bellavance M. A. · Int. J. Pharm. · 2010 · 395 · 25110.1016/j.ijpharm.2010.05.017 ↗
63. Vaidya B. · Int. J. Pharm. · 2011 · 403 · 25410.1016/j.ijpharm.2010.10.028 ↗
64. Fujita T. · J. Control. Release · 2008 · 129 · 12410.1016/j.jconrel.2008.04.010 ↗
65. Xu Z. H. · Biomacromolecules · 2008 · 9 · 311910.1021/bm800706f ↗